SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Icosavax, Inc. (Nasdaq – ICVX)

BALA CYNWYD – December 12, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Icosavax, Inc. (“Icosavax” or the “Company”) (Nasdaq – ICVX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to AstraZeneca PLC (Nasdaq – AZN). Under the terms of the agreement, AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.

The investigation concerns whether the Icosavax Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether AstraZeneca is paying fair value to shareholders of the Company.

If you own shares of Icosavax stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.